Fig. 4

Occurrence of Klebsiella spp. in clinical settings, as determined by ribosomal marker MALDI-TOF MS method. A Occurrence of Klebsiella groups and species in eight healthcare centres from Israel (n = 1), Spain (n = 1), Switzerland (n = 4) and the Netherlands (n = 2), sorted by increasing occurrence of the K. oxytoca group. B Occurrence of Klebsiella groups and species in patient samples from various isolation sites. “Primary sterile sites” includes deep wounds, aspirates and deep tissues; “Respiratory tract” includes sputum, bronchoalveolar lavage and tracheal secretion; “Superficial swabs” includes swabs from superficial wounds and skin infections. C Antibiotic resistance of Klebsiella spp. (BENI = beta lactams with beta-lactamase inhibitors, CEF3 = 3rd-generation cephalosporins, CEF4 = 4th-generation cephalosporins, AGLY = aminoglycosides, CARBA = carbapenems, CHIN = quinolones, PMX = polymyxins). Please note that the colour grading is on log-scale